辛伐他汀强化降脂治疗对不稳定心绞痛患者血浆高敏C-反应蛋白水平的影响

目的:研究常规降脂(辛伐他汀20mg/d)和强化降脂(辛伐他汀40mg/d)治疗1月后不稳定心绞痛(UAP)患者血浆高敏C反应蛋白(hs-CRP)浓度的变化,探讨短期强化降脂治疗对hs-CRP水平的影响.方法:选取不稳定心绞痛患者76例,均经冠状动脉造影证实,被随机分为常规降脂治疗组和强化降脂治疗组.在接受同样规范化治疗基础上,常规降脂组和强化降脂组分别接受辛伐他汀20mg/d和40mg/d治疗1月,测定治疗前、后血浆hs-CRP浓度.结果:降脂治疗1月后,常规降脂组治疗后Hs-CRP浓度与治疗前无明显变化,而强化降脂组治疗后Hs-CRP浓度较治疗前显著下降(P＜0.05),并且明显低于同期常规降脂治疗组(P＜0.05).血浆Hs-CRP浓度降低与血脂变化无显著相关.结论:强化降脂治疗可以在短期内有效降低不稳定心绞痛患者hs-CRP浓度.

Influence of Reinforced Lipid-lowering Treatment with Simvastatin on the Plasma Concentration of High-Sensitivity C-Reactive Protein in Patients with Unstable Angina Pectoris

Objective: To study the changes of plasma high-sensitivity C-reactive protein (hs-CRP) concentrations in patients with unstable angina pectoris (UAP) after one-month treatment with simvastatin 20mg or 40mg per day, and explore the influence of reinforced lipid-lowering therapy on hs-CRP in short term.Methods:76 cases of unstable angina pectoris diagnosised by angiocardiography were randomly divided into two groups to accept either simvastatin 20mg per day as routine lipid-lowering group (ROU group,n=38) or simvastatin 40mg per day as reinforced lipid-lowering group (REI group, n=38) of one month at the base of routine therapy. The concentrations of plasma hs-CRP of all patients were measured before and after theray. Results: After one month, the plasma hs-CRP concentrations did not significantly changed in ROU group comparing to the baseline, while in REI group, the hs-CRP concentrations were significantly decreased, and were evidently lower than that of patients in ROU group at the same period. The reduction of plasma hs-CRP concentration was not significantly related to the changes of plasma lipid levels. Conclusion: Lipid-lowering therapy with simvastatin 40mg per day can effectively reduce the plasma hs-CRP concentrations in patients with UAP in short-term.